I-MAB Biopharma Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Public, Subsidiary

Established: 2016-08-24

Employees: 251

Market Cap: $101.9M

Website: http://www.i-mabbiopharma.com

Clinical Trials

Expanded Access Protocol for Subjects With Relapsed or Refractory Advanced Solid Tumors Receiving TJ210001

Conditions: Solid Tumor Metastatic Cancer Advanced Cancer

First Posted Date: 2022-08-23

Last Posted Date: 2022-10-18

Lead Sponsor: I-Mab Biopharma US Limited

Registration Number: NCT05511350

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

Phase 2

Completed

Conditions: Ovarian Cancer
Head and Neck Cancer
Non Small Cell Lung Cancer
Gastrointestinal Cancer
Triple Negative Breast Cancer
Ovarian Carcinoma

Interventions: Drug: TJ004309

First Posted Date: 2021-08-11

Last Posted Date: 2023-10-12

Lead Sponsor: I-Mab Biopharma US Limited

Target Recruit Count: 25

Registration Number: NCT05001347

Locations: 🇺🇸
Innovative Clinical Research Institute, Whittier, California, United States
🇺🇸
Illinois Cancer Specialists, Arlington Heights, Illinois, United States
🇺🇸
Texas Oncology - The Woodlands, Gynecologic Oncology, The Woodlands, Texas, United States

and more 14 locations

A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: TJ210001 Injection

First Posted Date: 2021-07-01

Last Posted Date: 2023-03-14

Lead Sponsor: I-Mab Biopharma US Limited

Target Recruit Count: 25

Registration Number: NCT04947033

Locations: 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China

Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor
Advanced Cancer
Metastatic Cancer
Esophageal Adenocarcinoma
Gastric Cancer
Gastroesophageal Junction Carcinoma

Interventions: Drug: TJ033721
Drug: TJ033721, nivolumab, chemotherapy

First Posted Date: 2021-05-25

Last Posted Date: 2024-07-11

Lead Sponsor: I-Mab Biopharma US Limited

Target Recruit Count: 168

Registration Number: NCT04900818

Locations: 🇺🇸
Stern Center for Cancer Clinical Trials and Research, Orange, California, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 18 locations

Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer

Conditions: Cancer

First Posted Date: 2021-05-03

Last Posted Date: 2023-04-28

Lead Sponsor: I-Mab Biopharma US Limited

Registration Number: NCT04869501

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸
Arizona Oncology Associates, P.C., Tucson, Arizona, United States

Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor
Metastatic Cancer
Advanced Cancer

Interventions: Drug: TJ210001

First Posted Date: 2020-12-22

Last Posted Date: 2022-12-12

Lead Sponsor: I-Mab Biopharma US Limited

Target Recruit Count: 16

Registration Number: NCT04678921

Locations: 🇺🇸
Horizon Oncology Center, Lafayette, Indiana, United States
🇺🇸
University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado, United States
🇺🇸
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States

and more 1 locations

A Study of TJ003234 in Rheumatoid Arthritis Patients

Phase 1

Conditions: Rheumatoid Arthritis

Interventions: Biological: TJ003234 injection

First Posted Date: 2020-07-07

Last Posted Date: 2022-08-03

Lead Sponsor: I-Mab Biopharma US Limited

Target Recruit Count: 63

Registration Number: NCT04457856

Locations: 🇨🇳
Peking university people's Hospital, Beijing, Beijing, China
🇨🇳
The first affiliated hospital of bengbu medical college, Bengbu, Anhui, China
🇨🇳
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China

and more 2 locations

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)

Phase 2

Completed

Conditions: Coronavirus Disease 2019 COVID-19

Interventions: Drug: TJ003234
Drug: Placebo

First Posted Date: 2020-04-10

Last Posted Date: 2023-05-06

Lead Sponsor: I-Mab Biopharma US Limited

Target Recruit Count: 149

Registration Number: NCT04341116

Locations: 🇺🇸
UNM Hospitals, Albuquerque, New Mexico, United States
🇺🇸
OSF Healthcare Saint Francis Medical Center, Peoria, Illinois, United States
🇺🇸
University of Arkansas, Little Rock, Arkansas, United States

and more 11 locations

Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Phase 1

Completed

Conditions: Solid Tumor
Lymphoma

Interventions: Drug: TJ011133
Drug: Pembrolizumab
Drug: Rituximab

First Posted Date: 2019-05-02

Last Posted Date: 2024-07-01

Lead Sponsor: I-Mab Biopharma US Limited

Target Recruit Count: 98

Registration Number: NCT03934814

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇺🇸
University of Alabama - Birmingham, Birmingham, Alabama, United States

and more 16 locations

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy Adult Subjects

Interventions: Drug: TJ003234
Drug: Placebo

First Posted Date: 2019-01-04

Last Posted Date: 2019-12-18

Lead Sponsor: I-Mab Biopharma US Limited

Target Recruit Count: 32

Registration Number: NCT03794180

Locations: 🇺🇸
Pharmaron, Baltimore, Maryland, United States

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy